Pancreatic Cancer Research

ResearcherOkayama UniversityNo recent work listed

Kazuhiro Nouso

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2018-0008; OpenAlex author ID A5028697785. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper

Papers 13

  1. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1080/15384047.2021.1980312↗
  2. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Co-author DOI 10.1007/s10620-019-06006-6↗
  3. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2019.1638685↗
  4. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. First author DOI 10.1016/j.pan.2016.12.011↗
  5. Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer. Co-author DOI 10.1038/cgt.2016.31↗
  6. Synergistic anti-pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf-3 protein and peripheral blood mon… Co-author DOI 10.1111/jgh.13259↗
  7. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. First author DOI 10.1002/cncr.29364↗
  8. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine. First author DOI 10.1097/mpa.0000000000000321↗
  9. Corrigendum to “Loss of runt‐related transcription factor 3 induces gemcitabine resistance in pancreatic cancer” [Mol. Oncol. 7 (2013) 840–849] Co-author DOI 10.1016/j.molonc.2014.03.007↗
  10. Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. Co-author DOI 10.1111/jgh.12501↗
  11. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-012-0732-7↗
  12. Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2013.04.004↗
  13. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.009↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hironari Kato · 13 shared papers, 2012–2021 · strength 0.69
  2. Shigeru Horiguchi · 9 shared papers, 2013–2021 · strength 0.55
  3. Daisuke Uchida · 7 shared papers, 2014–2021 · strength 0.48
  4. Hideaki Kinugasa · 6 shared papers, 2015–2021 · strength 0.43
  5. Soichiro Ako · 4 shared papers, 2017–2021 · strength 0.35
  6. Kazuyuki Matsumoto · 4 shared papers, 2017–2021 · strength 0.35
  7. Kazuhide Yamamoto · 8 shared papers, 2012–2016 · strength 0.29
  8. Hiroyuki Okada · 4 shared papers, 2012–2020 · strength 0.26
  9. Shinichiro Muro · 3 shared papers, 2017–2021 · strength 0.26
  10. Koichiro Tsutsumi · 5 shared papers, 2012–2017 · strength 0.20
  11. Hiroyuki Terasawa · 2 shared papers, 2019–2021 · strength 0.19
  12. Koji Miyahara · 3 shared papers, 2013–2015 · strength 0.11
  13. Yuzo Umeda · 1 shared paper, 2021 · strength 0.10
  14. Ryuichi Yoshida · 1 shared paper, 2021 · strength 0.10
  15. Hiroyuki Okada · 1 shared paper, 2021 · strength 0.10
  16. Hiroaki Sawahara · 2 shared papers, 2016 · strength 0.10
  17. Shin‐Ichiro Nishimura · 2 shared papers, 2013–2015 · strength 0.07
  18. Hiroyuki M. OKADA · 1 shared paper, 2017 · strength 0.06
  19. Masakiyo Sakaguchi · 1 shared paper, 2016 · strength 0.05
  20. H Okada · 1 shared paper, 2016 · strength 0.05
  21. Ken Hirao · 1 shared paper, 2012 · strength 0.03
  22. Hirofumi Kawamoto · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.